LifeVantage Corporation

LFVN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $5.1M $9.8M $2.9M $2.5M $3.1M $12.9M $11.5M $7.4M
Depreciation & Amortization $2.8M $3.2M $3.6M $3.6M $3.3M $3.5M $2.8M $1.9M
Depreciation $2.4M $3.1M $3.4M $3.4M $3.1M $3.3M $2.6M $1.8M
Amortization $400.0K $100.0K $100.0K $100.0K $100.0K $100.0K $100.0K $100.0K
Stock-Based Compensation $2.3M $5.7M $3.3M $3.2M $1.8M $2.0M $4.9M $5.5M
Net Cash from Operating Activities $10.2M $11.9M $12.2M $6.8M $8.0M $16.3M $18.3M $17.8M
Investing Activities
Capital Expenditures $3.6M $1.4M $2.2M $3.1M $1.5M $3.7M $2.7M $2.5M
Business Acquisitions $3.7M $0 — — — — — —
Net Cash from Investing Activities $-7.3M $-1.4M $-2.2M $-3.1M $-1.5M $-3.7M $-2.7M $-4.5M
Financing Activities
Dividends Paid $2.3M $2.1M $6.9M $1.6M $378.0K $0 $0 —
Stock Repurchases $2.0M $3.1M $6.4M $822.0K $8.8M $11.9M $5.4M $4.7M
Net Cash from Financing Activities $-7.8M $-7.6M $-14.4M $-2.4M $-9.0M $-11.5M $-12.4M $-11.1M
Net Change in Cash $-5.3M $3.3M $-4.7M $1.4M $-3.0M $1.0M $3.3M $2.2M
Free Cash Flow $6.7M $10.5M $10.0M $3.8M $6.4M $12.5M $15.6M $15.3M
← Newer Page 1 of 2 Older →